SLC22A3 and coronary artery disorder: We show that variants in SLC22A3 alter glycemia, LDL-C and risk of CAD in a fashion that reflects the profile of actions seen with metformin in randomized trials, (Lamanna et al. 2011; Salpeter et al. 2008; Wulffele et al. 2004) providing further evidence that SLC22A3 may well be the pharmacological target of metformin.